Freenome secures £128m funds for multiomics cancer blood testing platform

Freenome secures £128m funds for multiomics cancer blood testing platform

14:16 EDT 25 Jul 2019 | Compelo Medical Devices

With the latest series B funding, led by RA Capital Management and Polaris Partners, Freenome’s total financing reached to $238m (£190.8m). The funding round saw participation from the

The post Freenome secures £128m funds for multiomics cancer blood testing platform appeared first on NS Medical Devices.

More From BioPortfolio on "Freenome secures £128m funds for multiomics cancer blood testing platform"